© 2022 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-02-01-2016
Pharmaceutical Executive
Life and Lipitor: Pfizer's Traci Medford-Rosow
February 09, 2016
Columns
36
2
In the patent scrum, a litigator finds her true self.
The Staying Power of Emerging Markets
February 08, 2016
Features
36
2
Whatever used to be wrong with the world of big Pharma could be fixed with a single tag phrase: emerging country markets. Most of the majors have invested heavily in this geographic segment, and the biggest of the big-companies like Novartis-now rely on it for more than a quarter of their global sales. Like all good things, however, there are shadows amidst the sunlight, and the task of turning volume sales into sustainable profits is getting harder.
Canada's Rx&D: Fresh Start for a New Era
February 05, 2016
Columns
36
2
Canada’s Rx&D, the industry’s oldest functioning trade association, recently changed its name-with a mission of bridging the many points of collaboration that drive the process of modern drugs, from discovery to market.
Morgan Moments: A Closer Reading of the JP Morgan Investor Conference
February 05, 2016
From the Editor
36
2
A closer reading of this year's JP Morgan investor conference identifies three areas where the insular, often maladroit tone of the industry-investor dialogue may be morphing to something more grounded in the larger societal context of healthcare.
Pharma dot-gov: A New Business Model
February 05, 2016
Features
36
2
An advocate of business system automation in the global pharma supply chain offers a six-pronged approach to adapting to the realities of a new age of mounting regulation and customer expectations.
Congress to Keep a Close Watch on FDA
February 01, 2016
Columns
36
2
More oversight of regulatory programs and policies planned by GOP critics.
The Creative Impulse: Defending Pharma and Health DTC
February 01, 2016
Columns
36
2
Defending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.
Bracing for ‘Brexit’?
February 01, 2016
Columns
36
2
What the drug industry stands to gain - or lose - from the unthinkable: Britain departing the European Union.
Securing Cipla’s Future
February 01, 2016
Features
36
2
Pharm Exec interviews Subhanu Saxena, CEO of India pharma giant Cipla, who discusses the longtime emerging market champion’s strategic plans to raise its geographic profile and secure the company’s future in the US.
Country Report: South Africa
February 01, 2016
Special Sponsored Section
36
2
In tandem with South Africa’s institutional advancements, driven by sweeping social and macroeconomic reforms, the pharma industry in the region is capitalizing on its core fundamentals: rising consumer disposable income, a positive demographic profile linked to an aging population, and a diverse disease burden requiring novel cures and treatments.
Pharmaceutical Executive, February 2016 Issue (PDF)
February 01, 2016
Issue PDF
36
2
Click the title above to open the Pharmaceutical Executive February 2016 issue in an interactive PDF format.